Empowered Funds LLC Invests $443,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Empowered Funds LLC acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,348 shares of the medical research company's stock, valued at approximately $443,000.

Several other large investors have also modified their holdings of BIO. Gladius Capital Management LP purchased a new position in Bio-Rad Laboratories in the third quarter valued at approximately $32,000. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the period. Point72 Hong Kong Ltd purchased a new position in Bio-Rad Laboratories in the third quarter valued at approximately $55,000. Quarry LP raised its holdings in Bio-Rad Laboratories by 38.1% in the third quarter. Quarry LP now owns 297 shares of the medical research company's stock valued at $99,000 after buying an additional 82 shares during the period. Finally, Assetmark Inc. raised its holdings in Bio-Rad Laboratories by 84.8% in the third quarter. Assetmark Inc. now owns 305 shares of the medical research company's stock valued at $102,000 after buying an additional 140 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 2.2 %

Shares of BIO traded down $6.15 during mid-day trading on Friday, reaching $279.48. 334,706 shares of the stock traded hands, compared to its average volume of 256,792. The firm has a market cap of $7.83 billion, a price-to-earnings ratio of -4.30 and a beta of 0.90. The stock has a fifty day simple moving average of $332.88 and a 200 day simple moving average of $334.33. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the topic of several research reports. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.